Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05093504 · ClinicalTrials.gov registry record · NA
Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)
A NA study, sponsored by CytoSorbents.
- Terminated
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT05093504: Clinical Trial NA study, sponsored by CytoSorbents.
NCT05093504 is a NA study that was terminated before completion, run by CytoSorbents. The registered enrollment target is 9 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05093504, a NA study, was terminated before completion, sponsored by CytoSorbents.
- TERMINATED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
Prospective, Multicenter, Double-blind, Randomized, Study to Evaluate DrugSorb-ATR Removal of Apixaban and Rivaroxaban to Reduce Likelihood of Serious Bleeding in Patients Undergoing Urgent Cardiothoracic Surgery
Primary Outcome
Incidence of clinically significant perioperative bleeding events, as evaluated by a ranked composite endpoint
Interventions
- DEVICE Sham comparator
- DEVICE DrugSorb-ATR system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-12-27 |
| Est. Completion | 2024-01-29 |
| Phase | NA |
Why NCT05093504 stopped before completion
NCT05093504 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham comparator is the first listed.
NCT05093504 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05093504 about?
NCT05093504 is a clinical study titled "Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)". Prospective, Multicenter, Double-blind, Randomized, Study to Evaluate DrugSorb-ATR Removal of Apixaban and Rivaroxaban to Reduce Likelihood of Serious Bleeding in Patients Undergoing Urgent Cardiothoracic Surgery
What is the current status of trial NCT05093504?
This trial is currently terminated. It is a NA study. The enrollment target is 9 participants. The study started on 2021-12-27. Estimated completion is 2024-01-29.
What interventions are being tested in trial NCT05093504?
The interventions under investigation include: Sham comparator (DEVICE), DrugSorb-ATR system (DEVICE).
Who is sponsoring clinical trial NCT05093504?
This trial is sponsored by CytoSorbents, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05093504's enrollment target sits among peer trials
9 1975th of 2000 higher than 25 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI